Cargando…

Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine

Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides’ (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis. Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of sci...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Yeonseo, Kang, Jihyun, Hwang, Sejung, Chung, Jae-Yong, Cho, Joo-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551744/
https://www.ncbi.nlm.nih.gov/pubmed/37810628
http://dx.doi.org/10.12793/tcp.2023.31.e12
_version_ 1785115837458284544
author Jang, Yeonseo
Kang, Jihyun
Hwang, Sejung
Chung, Jae-Yong
Cho, Joo-Youn
author_facet Jang, Yeonseo
Kang, Jihyun
Hwang, Sejung
Chung, Jae-Yong
Cho, Joo-Youn
author_sort Jang, Yeonseo
collection PubMed
description Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides’ (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis. Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of scientists and researchers in recent years. Previous studies have also observed CP-I and CP-III levels as clinical biomarkers for predicting OATP1B inhibition in drug–drug interaction studies. To establish an accurate ultra-high performance liquid chromatography–mass spectrometry method for the quantitation of CP-I and CP-III, we reviewed previous methodological publications and applied them to a clinical pharmacology study using a human urine matrix. We used 13.25 M formic acid as a working solution for internal standards (CP-I (15)N(4) and CP-III d(8)) to avoid isobaric interference. The calibration curve showed good linearity in the range of 1–100 ng/mL, with a correlation coefficient (R(2)) higher than 0.996 in each validation batch. Both the between-run and within-run assays achieved good precision and accuracy, and we found that both CP-I and CP-III were stable in the pre-study validation. The method exhibited suitable dilution integrity, allowing for the re-analysis of samples with concentrations exceeding the upper limit of quantification through dilution. Overall, the application of the described method in a clinical study revealed that it can be utilized effectively to monitor drug–drug interactions mediated by OATP1B.
format Online
Article
Text
id pubmed-10551744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Society for Clinical Pharmacology and Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-105517442023-10-06 Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine Jang, Yeonseo Kang, Jihyun Hwang, Sejung Chung, Jae-Yong Cho, Joo-Youn Transl Clin Pharmacol Original Article Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides’ (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis. Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of scientists and researchers in recent years. Previous studies have also observed CP-I and CP-III levels as clinical biomarkers for predicting OATP1B inhibition in drug–drug interaction studies. To establish an accurate ultra-high performance liquid chromatography–mass spectrometry method for the quantitation of CP-I and CP-III, we reviewed previous methodological publications and applied them to a clinical pharmacology study using a human urine matrix. We used 13.25 M formic acid as a working solution for internal standards (CP-I (15)N(4) and CP-III d(8)) to avoid isobaric interference. The calibration curve showed good linearity in the range of 1–100 ng/mL, with a correlation coefficient (R(2)) higher than 0.996 in each validation batch. Both the between-run and within-run assays achieved good precision and accuracy, and we found that both CP-I and CP-III were stable in the pre-study validation. The method exhibited suitable dilution integrity, allowing for the re-analysis of samples with concentrations exceeding the upper limit of quantification through dilution. Overall, the application of the described method in a clinical study revealed that it can be utilized effectively to monitor drug–drug interactions mediated by OATP1B. Korean Society for Clinical Pharmacology and Therapeutics 2023-09 2023-08-23 /pmc/articles/PMC10551744/ /pubmed/37810628 http://dx.doi.org/10.12793/tcp.2023.31.e12 Text en Copyright © 2023 Translational and Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/It is identical to the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original Article
Jang, Yeonseo
Kang, Jihyun
Hwang, Sejung
Chung, Jae-Yong
Cho, Joo-Youn
Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title_full Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title_fullStr Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title_full_unstemmed Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title_short Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
title_sort quantification of oatp1b1 endogenous metabolites coproporphyrin i and iii in human urine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551744/
https://www.ncbi.nlm.nih.gov/pubmed/37810628
http://dx.doi.org/10.12793/tcp.2023.31.e12
work_keys_str_mv AT jangyeonseo quantificationofoatp1b1endogenousmetabolitescoproporphyriniandiiiinhumanurine
AT kangjihyun quantificationofoatp1b1endogenousmetabolitescoproporphyriniandiiiinhumanurine
AT hwangsejung quantificationofoatp1b1endogenousmetabolitescoproporphyriniandiiiinhumanurine
AT chungjaeyong quantificationofoatp1b1endogenousmetabolitescoproporphyriniandiiiinhumanurine
AT chojooyoun quantificationofoatp1b1endogenousmetabolitescoproporphyriniandiiiinhumanurine